Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2025 financial and ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), a biotechnology company that pioneered the use of human hyaluronidase ...

Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a ...

Halozyme Therapeutics (NASDAQ:HALO) on Thursday announced a lawsuit against Merck (NYSE:MRK) over allegations that an ...

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...

Biopharmaceutical company Halozyme Therapeutics, Inc. (HALO) filed a patent infringement lawsuit against Merck & Co., Inc.

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...

In today's Pharmalittle roundup, we're reading about Roche and Merck struggles with tariffs, NEJM quizzed by U.S. attorney, ...

(RTTNews) - Halozyme Therapeutics (HALO) filed a patent infringement lawsuit against Merck Sharp & Dohme Corp. in U.S. District Court in New Jersey. Halozyme believes the subcutaneous formulation ...

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto ...

Halozyme (HALO) filed a patent infringement lawsuit against Merck (MRK) in U.S. District Court in New Jersey. Halozyme believes the ...